AstraZeneza's new crown vaccine, AZD1222, produces an immune response in older groups

Just days after the FDA restarted Trials of AstraZeneta III's COVID-19 vaccine, the company said its new coronavirus vaccine, AZD1222, had successfully produced an immune response in the elderly and young populations.
According to U.S. television station CNBC, the candidate vaccine AZD1222 not only showed efficacy in older patients (those most at risk of COVID-19), Butecon also found that the drug candidate had fewer adverse events in older patients.
, the trial was briefly halted because the vaccine caused severe neurological reactions in two trial participants ( one in the United States and one in the United Kingdom).
the safety of vaccines and trials has been reviewed and approved by regulators in many countries.
fda approved the resumption of phase III studies of the AZD1222 vaccine in the United States.
month, the vaccine resumed trials in the UK, Brazil and other countries.
AstraZeneta spokesman told CNBC,
The older and younger populations have similar immune responses and are less responsive in older adults (with a higher severity of COVID-19)."
July, the company released positive data from the vaccine's Phase I trial, showing that AZD1222 produces both meso-antibodies in patients and immune T cells that cause the COVID-19 virus.
, according to Oxford University, AstraZenecom's partner in developing a candidate vaccine, the vaccine can cause t-cell reactions within 14 days of vaccination and antibody reactions within 28 days.
believes the vaccine could provide a new coronavirus protection period of about a year.
and CNBC that the latest findings and more detailed reports of the ongoing AZD1222 trial are expected soon.
AstraZeneta's COVID-19 candidate vaccine, AZD1222, is a weakened adenovirus based on a viral vector, developed by the Jenner Institute at Oxford University and in collaboration with the Oxford Vaccine Team, using a viral vector based on a weak version of the adenovirus, which is loaded with genetic material from the SARS-CoV-2 spike protein.
, a surface prickly protein is produced, which triggers an attack on the immune system if the patient is later infected with the new coronavirus.
U.S. federal government's Opera Warp Speed program provided financial support for the vaccine candidate in the U.S. to develop a new coronavirus vaccine as soon as possible.
If the vaccine is eventually regulatoryly assessed and successfully produced, AstraZeneta plans to produce up to 2 billion doses of the vaccine, of which 400 million are expected to be used in the United States and the United Kingdom and 1 billion in low- and middle-income countries.
, AstraZenecom's vaccine is expected to be one of the earliest available COVID-19 vaccines in the United States and Western Europe.
AstraZeneta on Friday that several countries had begun rolling reviews of the vaccine.
dozens of candidate vaccines worldwide are being clinically evaluated, some of which are already in late-stage testing before formal approval can be sought.
, Pfizer and BioNTech will all have Phase III research data in the coming weeks.
, chief executive of Pfizer, said Pfizer could seek emergency authorization by the end of November if the test data were good.
, chief executive of Moderna, also said it expected to seek emergency authorization for the company's vaccine products in December.
astray, said the results of the Phase III study on the candidate vaccine, AZD1222, are expected later this year, depending on the community infection rate at the site where the clinical trial was conducted.
source: AstraZeneca's COVID-19 Vaccine Boosts Immune Response in Older, Adults